



24th June 2025

Cambridge Cognition Holdings plc  
("Cambridge Cognition", the "Company" or the "Group")

**Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment**

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved positive topline results from its Phase I clinical trial of MT1988, a novel treatment for cognitive impairment associated with schizophrenia (CIAS).

The positive Phase I results, which demonstrated favourable safety and tolerability profiles for MT1988, represent an important milestone in addressing CIAS, which is a core aspect of schizophrenia that significantly impacts patients' daily functioning yet remains without approved treatment options. These results support the advancement of MT1988 into Phase II clinical development, targeting CIAS and related conditions.

Cambridge Cognition's proprietary digital cognitive assessment technologies were instrumental in the early development phases of understanding cognitive endpoints in this therapeutic area, contributing to the foundation upon which Monument Therapeutics has built its clinical programme.

Monument Therapeutics was originally established by Cambridge Cognition as an independent precision neuroscience company to develop novel treatments for cognitive disorders, and the Group retains both an equity stake and a royalty structure in Monument Therapeutics that entitles it to future revenues arising from commercialisation of MT1988 and other programmes.

**Rob Baker, Joint Managing Director and Chief Operating Officer, commented:**

"We are delighted to see Monument Therapeutics achieve this significant milestone with MT1988. These promising results validate Monument's innovative approach to addressing the critical unmet need in CIAS and we remain hopeful that our investment, as well as potential future royalties, will be significantly value enhancing."

**Enquiries:**

<b>Cambridge Cognition Holdings plc</b> Rob Baker, Joint Managing Director and Chief Operating Officer	Tel: 012 2381 0700 <a href="mailto:press@camcog.com">press@camcog.com</a>
<b>Panmure Liberum Limited (NOMAD and Joint Broker)</b> Freddy Crossley / Will Goode / Mark Rogers Rupert Dearden	Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking)
<b>Dowgate Capital Limited (Joint Broker)</b> David Poutney / James Serjeant	Tel: 020 3903 7715
<b>Hudson Sandler (Financial PR and IR)</b> Dan de Belder / Hattie Dreyfus / Jackson Redley	Tel: 020 7796 4133 <a href="mailto:cog@hudsonsandler.com">cog@hudsonsandler.com</a>

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment. Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

- **Clinical Studies** for new pharmaceuticals;
- **Academic Research** for scientists to understand CNS disorders;
- **Healthcare** to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- **Consumer Health & Wellness** to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: [www.cambridgecognition.com](http://www.cambridgecognition.com)

**About Monument Therapeutics**

Monument Therapeutics applies a unique novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments. Lead asset MT1988 targets the cognitive symptoms of schizophrenia, which are extremely costly for society and profoundly impact the affected individuals and their quality of life.

For more information, please visit [www.monumenttx.com](http://www.monumenttx.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFZGZVVFNGKZM